lofexidine (Lucemyra)

From Aaushi
Jump to navigation Jump to search

Indications

Mechanism of action

More general terms

References

  1. US WorldMeds. Mar 27, 2018, FDA Advisory Committee Votes in Favor of LUCEMYRA<TM> (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms. https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-in-favor-of-lucemyra-lofexidine-for-the-mitigation-of-opioid-withdrawal-symptoms-300620526.html
    FDA Advisory Committees Briefing Information for the March 27, 2018 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC). https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm602415.htm
  2. 2.0 2.1 Brooks M FDA Approves First Nonopioid Drug for Opioid Withdrawal. Medscape - May 16, 2018. https://www.medscape.com/viewarticle/896736
    FDA News Release. May 16, 2018 FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm

Database